Literature DB >> 11244498

Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells.

M E Balañá1, L Labriola, M Salatino, F Movsichoff, G Peters, E H Charreau, P V Elizalde.   

Abstract

The present study focused on interactions between signaling pathways activated by progestins and by type I and II receptor tyrosine kinases (RTKs) in mammary tumors. An experimental model in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in Balb/c mice was used. MPA-stimulated proliferation, both in vivo and in vitro, of progestin-dependent tumors induced up-regulation of ErbB-2 protein levels and tyrosine phosphorylation of this receptor. Combinations of antisense oligodeoxynucleotides (ASODNs) directed to ErbB-2 mRNA with ASODNs directed to the insulin-like growth factor-I receptor (IGF-IR) were used to study the effect of the simultaneous block of these receptors on the MPA-induced proliferation of epithelial cells from the progestin-dependent C4HD line. Neither synergistic nor additive effects on the inhibition of MPA-induced proliferation of C4HD cells were observed as a result of the combination of these ASODNs. Suppression of IGF-IR expression by ASODNs resulted in complete abrogation of MPA-induced phosphorylation of ErbB-2 in C4HD cells, whereas blockage of ErbB-2 did not affect IGF-IR phosphorylation. These results show the existence of a hierarchical interaction between IGF-IR and ErbB-2, by means of which IGF-IR directs ErbB-2 phosphorylation. We demonstrated, for the first time, that this hierarchical interaction involves physical association of both receptors, resulting in the formation of a heteromeric complex. Furthermore, confocal laser microscopy experiments demonstrated that MPA was able to induce co-localization of ErbB-2 and IGF-IR. This hetero-oligomer was also found in MCF-7 human breast cancer cells in which association of IGF-IR and ErbB-2 was induced by heregulin and IGF-I. Oncogene (2001) 20, 34 - 47.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11244498     DOI: 10.1038/sj.onc.1204050

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  37 in total

Review 1.  A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Authors:  Pravin T P Kaumaya
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

Authors:  R I Nicholson; I R Hutcheson; H E Jones; S E Hiscox; M Giles; K M Taylor; J M W Gee
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

3.  A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.

Authors:  Jonas A de Souza; Darren W Davis; Yujian Zhang; Arun Khattri; Tanguy Y Seiwert; Serdal Aktolga; Stuart J Wong; Mark F Kozloff; Sreenivasa Nattam; Mark W Lingen; Rangesh Kunnavakkam; Kerstin M Stenson; Elizabeth A Blair; Jeffrey Bozeman; Janet E Dancey; Everett E Vokes; Ezra E W Cohen
Journal:  Clin Cancer Res       Date:  2012-02-27       Impact factor: 12.531

4.  Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.

Authors:  Wolfgang J Köstler; Gernot Hudelist; Werner Rabitsch; Klaus Czerwenka; Ruth Müller; Christian F Singer; Christoph C Zielinski
Journal:  J Cancer Res Clin Oncol       Date:  2005-09-24       Impact factor: 4.553

5.  Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma.

Authors:  Jinu Abraham; Suresh I Prajapati; Koichi Nishijo; Beverly S Schaffer; Eri Taniguchi; Aoife Kilcoyne; Amanda T McCleish; Laura D Nelon; Francis G Giles; Argiris Efstratiadis; Robin D LeGallo; Brent M Nowak; Brian P Rubin; Suman Malempati; Charles Keller
Journal:  Mol Cancer Ther       Date:  2011-03-29       Impact factor: 6.261

6.  Involvement of HER-2/neu and metastasis-related proteins in the development of ileal neuroendocrine tumors.

Authors:  Cinzia Azzoni; Lorena Bottarelli; Stefano Cecchini; Costanza Lagrasta; Silvia Pizzi; Tiziana D'Adda; Elisa Tamburini; Guido Rindi; Cesare Bordi
Journal:  Virchows Arch       Date:  2011-03-29       Impact factor: 4.064

7.  ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis.

Authors:  Craig I Campbell; James J Petrik; Roger A Moorehead
Journal:  Mol Cancer       Date:  2010-09-08       Impact factor: 27.401

Review 8.  Tracking progesterone receptor-mediated actions in breast cancer.

Authors:  Todd P Knutson; Carol A Lange
Journal:  Pharmacol Ther       Date:  2013-11-26       Impact factor: 12.310

Review 9.  Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.

Authors:  Giampaolo Tortora; Roberto Bianco; Gennaro Daniele; Fortunato Ciardiello; James A McCubrey; Maria Rosaria Ricciardi; Ludovica Ciuffreda; Francesco Cognetti; Agostino Tafuri; Michele Milella
Journal:  Drug Resist Updat       Date:  2007-05-07       Impact factor: 18.500

10.  Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity.

Authors:  Malathy P V Shekhar; Steven Santner; Kathryn A Carolin; Larry Tait
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.